Display options
Cite
Zou L, Wang D, Hu Y, et al. Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget. 2017;8(36):60453-60468doi: 10.18632/oncotarget.19728.
Zou, L., Wang, D., Hu, Y., Fu, C., Li, W., Dai, L., Yang, L., & Zhang, J. (2017). Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget, 8(36), 60453-60468. https://doi.org/10.18632/oncotarget.19728
Zou, Liang, et al. "Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles." Oncotarget vol. 8,36 (2017): 60453-60468. doi: https://doi.org/10.18632/oncotarget.19728
Zou L, Wang D, Hu Y, Fu C, Li W, Dai L, Yang L, Zhang J. Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles. Oncotarget. 2017 Jul 31;8(36):60453-60468. doi: 10.18632/oncotarget.19728. eCollection 2017 Sep 01. PMID: 28947984; PMCID: PMC5601152.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 31;8(36):60453-60468. doi: 10.18632/oncotarget.19728. eCollection 2017 Sep 01.

Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles.

Oncotarget

Liang Zou, Di Wang, Yichen Hu, Chaomei Fu, Wei Li, Liping Dai, Lin Yang, Jinming Zhang

Affiliations

  1. School of Medicine, Chengdu University, Chengdu 610106, China.
  2. College of Pharmacy and Biological Engineering, Chengdu University, Chengdu 610106, China.
  3. College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

PMID: 28947984 PMCID: PMC5601152 DOI: 10.18632/oncotarget.19728

Abstract

Paclitaxel (PTX) is frequently suffered from multidrug resistance (MDR), resulting in lower chemotherapeutic efficacy and even chemotherapy failure. To combine the P-glycolprotein (P-gp) inhibitor would be a useful strategy to overcome MDR. However, what is needed now is an efficient vehicle to deliver multiple drugs into tumor simultaneously. In this study, PTX and Borneol (BNL), a natural compound with P-gp inhibition effect confirmed in intestinal absorption, were co-loaded in the fabricated PEG-PAMAM nanoparticle (NPs) by a one-step nano-precipitation method with high drug loading efficiency, narrow size distribution and low hemolysis rate. Based on P-gp inhibition activity of BNL, confirmed by drug efflux test and molecular docking model, the combination of PTX and BNL could improve intracellular concentration of PTX in A2780/PTX cells. Furthermore, compared to both free PTX and PTX+BNL, PB/NPs and P/NPs plus BNL exhibited higher cellular uptake and cytotoxicity in A2780/PTX cells, as well as the decreased MMP and enhanced apoptosis rate. More importantly, although PB/NPs and P/NPs+B showed similar tumor accumulation in tumor-bearing mice, PB/NPs could significantly decrease tumor growth of A2780/PTX tumor-bearing mice, in comparison to P/NPs+B. These results indicated the advantage of PTX and BNL co-delivery NPs for MDR reversal. These findings demonstrate that the co-delivery nano-sized system comprised by PEG-PAMAM polymer with PTX and BNL co-loaded would be a promising candidate for MDR treatment.

Keywords: MDR reversal; P-gp inhibition; PAMAM dendrimer; borneol; co-delivery

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work and declare that all figures are original and have not published.

References

  1. Mol Pharm. 2016 Jul 5;13(7):2363-75 - PubMed
  2. J Comput Chem. 2009 Dec;30(16):2785-91 - PubMed
  3. Colloids Surf B Biointerfaces. 2016 Nov 1;147:242-249 - PubMed
  4. Mol Pharm. 2014 Sep 2;11(9):3196-209 - PubMed
  5. Sci Rep. 2017 Feb 14;7:42465 - PubMed
  6. Drug Dev Ind Pharm. 2011 Apr;37(4):419-27 - PubMed
  7. Expert Opin Drug Deliv. 2013 Dec;10(12):1687-98 - PubMed
  8. Cancer Treat Rev. 2008 Nov;34(7):592-602 - PubMed
  9. Int J Pharm. 2017 Mar 15;519(1-2):352-364 - PubMed
  10. Arch Pharm Res. 2011 Jul;34(7):1161-70 - PubMed
  11. Sci Rep. 2016 Mar 07;6:22390 - PubMed
  12. PLoS One. 2014 Oct 17;9(10):e110611 - PubMed
  13. Carbohydr Polym. 2015 Sep 20;129:25-34 - PubMed
  14. ACS Appl Mater Interfaces. 2016 Feb;8(7):4368-77 - PubMed
  15. Int J Pharm. 2016 Nov 20;513(1-2):8-16 - PubMed
  16. Ecancermedicalscience. 2016 Mar 08;10:626 - PubMed
  17. Colloids Surf B Biointerfaces. 2015 Dec 1;136:413-23 - PubMed
  18. Int J Mol Sci. 2015 Nov 18;16(11):27576-88 - PubMed
  19. J Biomater Sci Polym Ed. 2016 Nov;27(16):1645-58 - PubMed
  20. Nanoscale. 2015 Oct 14;7(38):15763-79 - PubMed
  21. Mini Rev Med Chem. 2008 Aug;8(9):889-900 - PubMed
  22. Biomaterials. 2015 Dec;73:284-95 - PubMed
  23. Eur J Pharmacol. 2016 Sep 5;786:194-203 - PubMed
  24. PLoS One. 2014 Jul 03;9(7):e101414 - PubMed
  25. Acta Biomater. 2016 Oct 1;43:14-29 - PubMed
  26. Expert Opin Drug Metab Toxicol. 2016 Sep;12 (9):1021-33 - PubMed
  27. Chem Biol Interact. 2015 Jun 25;235:76-84 - PubMed
  28. Food Funct. 2015 Mar;6(3):740-8 - PubMed
  29. J Pharm Pharmacol. 2016 Aug;68(8):1010-20 - PubMed
  30. Biochim Biophys Acta. 2016 Dec;1866(2):266-275 - PubMed
  31. Wien Med Wochenschr. 2014 Nov;164(21-22):456-60 - PubMed

Publication Types